Disc Medicine Files 8-K on Operations and Financials
Ticker: IRON · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1816736
| Field | Detail |
|---|---|
| Company | Disc Medicine, Inc. (IRON) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $615.9 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, disclosure
TL;DR
Disc Medicine dropped an 8-K on 10/20/25 covering financials and operations.
AI Summary
Disc Medicine, Inc. filed an 8-K on October 20, 2025, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure and other events, along with financial statements and exhibits. The company, formerly known as Gemini Therapeutics, Inc. and FS Development Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This 8-K filing provides crucial updates on Disc Medicine's financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Disc Medicine, Inc. (company) — Registrant
- Gemini Therapeutics, Inc. (company) — Former company name
- FS Development Corp. (company) — Former company name
- October 20, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Watertown, Massachusetts (location) — Principal executive office address
FAQ
What is the primary purpose of this 8-K filing by Disc Medicine, Inc.?
The primary purpose of this 8-K filing is to report on Disc Medicine, Inc.'s results of operations and financial condition, as well as to provide updates on Regulation FD disclosures and other events.
When was this 8-K report filed?
This 8-K report was filed on October 20, 2025.
What were Disc Medicine, Inc.'s former names?
Disc Medicine, Inc. was formerly known as Gemini Therapeutics, Inc. and FS Development Corp.
In which state is Disc Medicine, Inc. incorporated?
Disc Medicine, Inc. is incorporated in Delaware.
What is the principal executive office address for Disc Medicine, Inc.?
The principal executive office address for Disc Medicine, Inc. is 321 Arsenal Street, Suite 101, Watertown, Massachusetts 02472.
Filing Stats: 1,648 words · 7 min read · ~5 pages · Grade level 15.1 · Accepted 2025-10-20 06:38:05
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Ma
- $615.9 million — f September 30, 2025 were approximately $615.9 million. The Company has not yet completed it
Filing Documents
- d272031d8k.htm (8-K) — 45KB
- d272031dex991.htm (EX-99.1) — 24KB
- d272031dex992.htm (EX-99.2) — 65KB
- g272031ex99_2p10g1.jpg (GRAPHIC) — 209KB
- g272031ex99_2p11g1.jpg (GRAPHIC) — 274KB
- g272031ex99_2p12g1.jpg (GRAPHIC) — 208KB
- g272031ex99_2p13g1.jpg (GRAPHIC) — 260KB
- g272031ex99_2p14g1.jpg (GRAPHIC) — 198KB
- g272031ex99_2p15g1.jpg (GRAPHIC) — 214KB
- g272031ex99_2p16g1.jpg (GRAPHIC) — 254KB
- g272031ex99_2p17g1.jpg (GRAPHIC) — 218KB
- g272031ex99_2p18g1.jpg (GRAPHIC) — 246KB
- g272031ex99_2p19g1.jpg (GRAPHIC) — 225KB
- g272031ex99_2p1g1.jpg (GRAPHIC) — 82KB
- g272031ex99_2p20g1.jpg (GRAPHIC) — 151KB
- g272031ex99_2p21g1.jpg (GRAPHIC) — 226KB
- g272031ex99_2p22g1.jpg (GRAPHIC) — 164KB
- g272031ex99_2p23g1.jpg (GRAPHIC) — 64KB
- g272031ex99_2p24g1.jpg (GRAPHIC) — 129KB
- g272031ex99_2p25g1.jpg (GRAPHIC) — 164KB
- g272031ex99_2p26g1.jpg (GRAPHIC) — 54KB
- g272031ex99_2p27g1.jpg (GRAPHIC) — 188KB
- g272031ex99_2p28g1.jpg (GRAPHIC) — 195KB
- g272031ex99_2p29g1.jpg (GRAPHIC) — 199KB
- g272031ex99_2p2g1.jpg (GRAPHIC) — 476KB
- g272031ex99_2p30g1.jpg (GRAPHIC) — 244KB
- g272031ex99_2p31g1.jpg (GRAPHIC) — 165KB
- g272031ex99_2p32g1.jpg (GRAPHIC) — 223KB
- g272031ex99_2p33g1.jpg (GRAPHIC) — 246KB
- g272031ex99_2p34g1.jpg (GRAPHIC) — 225KB
- g272031ex99_2p35g1.jpg (GRAPHIC) — 246KB
- g272031ex99_2p36g1.jpg (GRAPHIC) — 154KB
- g272031ex99_2p37g1.jpg (GRAPHIC) — 251KB
- g272031ex99_2p38g1.jpg (GRAPHIC) — 264KB
- g272031ex99_2p39g1.jpg (GRAPHIC) — 238KB
- g272031ex99_2p3g1.jpg (GRAPHIC) — 71KB
- g272031ex99_2p40g1.jpg (GRAPHIC) — 200KB
- g272031ex99_2p41g1.jpg (GRAPHIC) — 271KB
- g272031ex99_2p42g1.jpg (GRAPHIC) — 261KB
- g272031ex99_2p43g1.jpg (GRAPHIC) — 211KB
- g272031ex99_2p44g1.jpg (GRAPHIC) — 158KB
- g272031ex99_2p45g1.jpg (GRAPHIC) — 327KB
- g272031ex99_2p46g1.jpg (GRAPHIC) — 255KB
- g272031ex99_2p47g1.jpg (GRAPHIC) — 52KB
- g272031ex99_2p48g1.jpg (GRAPHIC) — 172KB
- g272031ex99_2p49g1.jpg (GRAPHIC) — 184KB
- g272031ex99_2p4g1.jpg (GRAPHIC) — 290KB
- g272031ex99_2p50g1.jpg (GRAPHIC) — 187KB
- g272031ex99_2p51g1.jpg (GRAPHIC) — 228KB
- g272031ex99_2p52g1.jpg (GRAPHIC) — 249KB
- g272031ex99_2p53g1.jpg (GRAPHIC) — 225KB
- g272031ex99_2p54g1.jpg (GRAPHIC) — 131KB
- g272031ex99_2p55g1.jpg (GRAPHIC) — 230KB
- g272031ex99_2p56g1.jpg (GRAPHIC) — 211KB
- g272031ex99_2p57g1.jpg (GRAPHIC) — 258KB
- g272031ex99_2p58g1.jpg (GRAPHIC) — 253KB
- g272031ex99_2p59g1.jpg (GRAPHIC) — 203KB
- g272031ex99_2p5g1.jpg (GRAPHIC) — 225KB
- g272031ex99_2p60g1.jpg (GRAPHIC) — 285KB
- g272031ex99_2p61g1.jpg (GRAPHIC) — 63KB
- g272031ex99_2p6g1.jpg (GRAPHIC) — 197KB
- g272031ex99_2p7g1.jpg (GRAPHIC) — 223KB
- g272031ex99_2p8g1.jpg (GRAPHIC) — 214KB
- g272031ex99_2p9g1.jpg (GRAPHIC) — 56KB
- g272031g1020095838601.jpg (GRAPHIC) — 4KB
- 0001193125-25-242959.txt ( ) — 17578KB
- iron-20251020.xsd (EX-101.SCH) — 3KB
- iron-20251020_lab.xml (EX-101.LAB) — 18KB
- iron-20251020_pre.xml (EX-101.PRE) — 11KB
- d272031d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: October 20, 2025 By: /s/ John Quisel Name: John Quisel, J.D., Ph.D. Title: Chief Executive Officer